Skip to content
PipDig
EUR/USD1.08537 +0.24%GBP/USD1.27311 -0.31%USD/JPY156.835 +0.42%XAU/USD4062.31 +0.67%BTC/USD96403.00 +2.16%

Forex News

Sernova, Seraxis say merger name is BetaNova Biotherapeutics

Sernova Biotherapeutics and Seraxis Holdings said their proposed merger name is BetaNova Biotherapeutics, with close expected in November 2026.

By Fiona McAllister, Global Markets EditorPipDig Newsroomอ่านฉบับภาษาไทย
  • Sernova Biotherapeutics and Seraxis Holdings named BetaNova Biotherapeutics as the proposed merger.
  • The close is expected in November 2026.
  • Sernova said the merger agreement date was September 8, 2026.

Merger

Sernova Biotherapeutics said the merger agreement date was September 8, 2026. Sernova Biotherapeutics and Seraxis Holdings identified BetaNova Biotherapeutics as the proposed merger.

Extreme close-up of two overlapping glass droplets on a glossy surface whose reflections create interlocking circular shapes in cool blue-green tones, softly focused with a low-contrast empty lower third.
Sernova, Seraxis say merger name is BetaNova Biotherapeutics

Sernova Biotherapeutics said October 1, 2026 is an event date. The close is expected in November 2026.

Companies

Jonathan Rigby is president and CEO of Sernova. Will Rust, Ph.D., is president and CEO of Seraxis.

Sernova Biotherapeutics' technology is the Cell Pouch Bio-hybrid Organ. BetaNova Biotherapeutics' focus is T1D islet cell replacement. Seraxis Holdings, Inc. has SR-02 and SR-03 stem cell-derived pancreatic islet programs.

Conference

Sernova Biotherapeutics also listed participation in Noble Capital Markets’ Emerging Growth Virtual Equity Conference.

Source: GlobeNewswire,